<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00466336</url>
  </required_header>
  <id_info>
    <org_study_id>200612012R</org_study_id>
    <nct_id>NCT00466336</nct_id>
  </id_info>
  <brief_title>Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices</brief_title>
  <official_title>Prediction of Hepatic Fibrosis in Patients With Chronic Hepatitis C by Biochemical and Duplex Doppler Indices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of our prospective study was to evaluate the value of Doppler parameters and
      compare the diagnostic accuracy of Doppler parameters with various biochemical indices in
      predicting significant hepatic fibrosis (≥ F2) and cirrhosis (F4) in chronic hepatitis C
      (CHC) patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is a global health problem, affecting about 3% of
      the world's population. Compared to patients with mild hepatic fibrosis, those with
      significant fibrosis are at risk of developing cirrhosis over a 10- to 20-year period. This
      fact suggests the need of early antiviral therapy in chronic hepatitis C (CHC) patients to
      prevent the development of cirrhosis and associated complications. For patients having
      cirrhosis, surveillance endoscopy and ultrasound for gastroesophageal varices and
      hepatocellular carcinoma are needed to minimize morbidity and mortality ). Furthermore,
      reduced treatment response and tolerability to antiviral therapy may be encountered in
      cirrhotic patients. An accurate assessment of hepatic fibrosis stage is therefore important
      for both diagnostic and therapeutic purposes.

      Liver biopsy has been recognized as the gold standard for assessing the grade of
      necroinflammation and stage of fibrosis. However, it is costly, and harbors risk of
      complications, including 20% of patient discomfort, 0.1-3% of significant morbidity, and
      0.02-0.24% of mortality. In addition, sampling error due to the non-uniform distribution of
      the parenchymal damage, as well as intra- and inter-observer variability is often
      encountered. A noninvasive tool to evaluate liver disease activity or fibrosis stage would be
      helpful, particularly in monitoring CHC patients over time.

      Noninvasive methods to evaluate the hepatic histology in HCV-infected patients include
      symptoms and signs, routine laboratory tests, serum markers of fibrosis and inflammation,
      quantitative tests of liver function, and radiological imaging. Previous studies have
      assessed the usefulness of noninvasive tests in predicting hepatic fibrosis. However, none of
      them showed satisfactory results, either due to lack of accuracy, accessibility,
      reproducibility or being expensive.

      Duplex Doppler ultrasonography (DDU), which is readily available and non-invasive, has been
      used for the assessment of splanchnic vascular hemodynamics in patients with chronic liver
      disease. Portal vein velocity (PVV) has been shown to be correlated with significant fibrosis
      or cirrhosis. Hepatic artery resistive index (HARI) and pulsatility index (HAPI) are
      associated with portal vein resistance and hepatic vein-portal vein pressure gradient (HPVG).
      Splenic artery resistive index (SARI) and pulsatility index (SAPI) are associated with portal
      vein resistance, cirrhosis and grade of esophageal varices (EV). Previous studies to evaluate
      the value of DDU in predicting liver histology are controversial, probably due to small
      patient number, diverse grading of liver histology, and large missing data.

      Thus, the purpose of our prospective study was to evaluate the value of Doppler parameters
      and compare the diagnostic accuracy of Doppler parameters with various biochemical indices in
      predicting significant hepatic fibrosis (≥ F2) and cirrhosis (F4) in chronic hepatitis C
      (CHC) patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Actual">503</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <condition>Hepatic Fibrosis</condition>
  <condition>Cirrhosis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis C patients with abnormal ALT levels (&gt; 2X ULN) with percutaneous liver
        biopsy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age older than 18 years

          -  Positive anti-HCV and HCV RNA for more than 6 months

          -  Alanine aminotransferase level more than twice the upper limit of normal (ULN)

        Exclusion Criteria:

          -  HBV and HCV co-infection

          -  HIV and HCV co-infection

          -  Heavy alcohol use (&gt; 50 gram/day)

          -  Autoimmune liver diseases

          -  Metabolic liver diseases

          -  Presence of hepatocellular carcinoma
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chen-Hua Liu, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Internal Medicine, National Taiwan Universitys Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <reference>
    <citation>National Institutes of Health Consensus Development Conference Panel statement: management of hepatitis C. Hepatology. 1997 Sep;26(3 Suppl 1):2S-10S. Review.</citation>
    <PMID>9305656</PMID>
  </reference>
  <reference>
    <citation>Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001 Jul 5;345(1):41-52. Review.</citation>
    <PMID>11439948</PMID>
  </reference>
  <reference>
    <citation>Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996 Jun;23(6):1334-40.</citation>
    <PMID>8675148</PMID>
  </reference>
  <reference>
    <citation>de Franchis R, Pascal JP, Ancona E, Burroughs AK, Henderson M, Fleig W, Groszmann R, Bosch J, Sauerbruch T, Soederlund C, et al. Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol. 1992 May;15(1-2):256-61. Review.</citation>
    <PMID>1506645</PMID>
  </reference>
  <reference>
    <citation>Daniele B, Bencivenga A, Megna AS, Tinessa V. Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology. 2004 Nov;127(5 Suppl 1):S108-12. Review.</citation>
    <PMID>15508073</PMID>
  </reference>
  <reference>
    <citation>Heathcote EJ, Shiffman ML, Cooksley WG, Dusheiko GM, Lee SS, Balart L, Reindollar R, Reddy RK, Wright TL, Lin A, Hoffman J, De Pamphilis J. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000 Dec 7;343(23):1673-80.</citation>
    <PMID>11106716</PMID>
  </reference>
  <reference>
    <citation>Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68,276 biopsies. J Hepatol. 1986;2(2):165-73.</citation>
    <PMID>3958472</PMID>
  </reference>
  <reference>
    <citation>Nord HJ. Biopsy diagnosis of cirrhosis: blind percutaneous versus guided direct vision techniques--a review. Gastrointest Endosc. 1982 May;28(2):102-4.</citation>
    <PMID>6211383</PMID>
  </reference>
  <reference>
    <citation>Garcia-Tsao G, Boyer JL. Outpatient liver biopsy: how safe is it? Ann Intern Med. 1993 Jan 15;118(2):150-3.</citation>
    <PMID>8416312</PMID>
  </reference>
  <reference>
    <citation>Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology. 2000 Sep;32(3):477-81.</citation>
    <PMID>10960438</PMID>
  </reference>
  <reference>
    <citation>McGill DB, Rakela J, Zinsmeister AR, Ott BJ. A 21-year experience with major hemorrhage after percutaneous liver biopsy. Gastroenterology. 1990 Nov;99(5):1396-400.</citation>
    <PMID>2101588</PMID>
  </reference>
  <reference>
    <citation>Maharaj B, Maharaj RJ, Leary WP, Cooppan RM, Naran AD, Pirie D, Pudifin DJ. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet. 1986 Mar 8;1(8480):523-5.</citation>
    <PMID>2869260</PMID>
  </reference>
  <reference>
    <citation>Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003 Dec;38(6):1449-57.</citation>
    <PMID>14647056</PMID>
  </reference>
  <reference>
    <citation>Colloredo G, Guido M, Sonzogni A, Leandro G. Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol. 2003 Aug;39(2):239-44.</citation>
    <PMID>12873821</PMID>
  </reference>
  <reference>
    <citation>Fontana RJ, Lok AS. Noninvasive monitoring of patients with chronic hepatitis C. Hepatology. 2002 Nov;36(5 Suppl 1):S57-64. Review.</citation>
    <PMID>12407577</PMID>
  </reference>
  <reference>
    <citation>Williams AL, Hoofnagle JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis. Gastroenterology. 1988 Sep;95(3):734-9.</citation>
    <PMID>3135226</PMID>
  </reference>
  <reference>
    <citation>Sheth SG, Flamm SL, Gordon FD, Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1998 Jan;93(1):44-8.</citation>
    <PMID>9448172</PMID>
  </reference>
  <reference>
    <citation>Park GJ, Lin BP, Ngu MC, Jones DB, Katelaris PH. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis? J Gastroenterol Hepatol. 2000 Apr;15(4):386-90.</citation>
    <PMID>10824882</PMID>
  </reference>
  <reference>
    <citation>Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003 Jan 27;163(2):218-24.</citation>
    <PMID>12546613</PMID>
  </reference>
  <reference>
    <citation>Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T; MULTIVIRC Group. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001 Apr 7;357(9262):1069-75.</citation>
    <PMID>11297957</PMID>
  </reference>
  <reference>
    <citation>Myers RP, Ratziu V, Imbert-Bismut F, Charlotte F, Poynard T; MULTIVIRC Group. Groupe d'Etude Multidisciplinaire sur les Pathologies Liées au Virus C. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol. 2002 Sep;97(9):2419-25.</citation>
    <PMID>12358267</PMID>
  </reference>
  <reference>
    <citation>Poynard T, Bedossa P. Age and platelet count: a simple index for predicting the presence of histological lesions in patients with antibodies to hepatitis C virus. METAVIR and CLINIVIR Cooperative Study Groups. J Viral Hepat. 1997 May;4(3):199-208.</citation>
    <PMID>9181529</PMID>
  </reference>
  <reference>
    <citation>Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003 Aug;38(2):518-26.</citation>
    <PMID>12883497</PMID>
  </reference>
  <reference>
    <citation>Forns X, Ampurdanès S, Llovet JM, Aponte J, Quintó L, Martínez-Bauer E, Bruguera M, Sánchez-Tapias JM, Rodés J. Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology. 2002 Oct;36(4 Pt 1):986-92.</citation>
    <PMID>12297848</PMID>
  </reference>
  <reference>
    <citation>Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005 Feb;128(2):343-50.</citation>
    <PMID>15685546</PMID>
  </reference>
  <reference>
    <citation>Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology. 2005 Jun;41(6):1376-82.</citation>
    <PMID>15915455</PMID>
  </reference>
  <reference>
    <citation>Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ; European Liver Fibrosis Group. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology. 2004 Dec;127(6):1704-13.</citation>
    <PMID>15578508</PMID>
  </reference>
  <reference>
    <citation>Gaiani S, Gramantieri L, Venturoli N, Piscaglia F, Siringo S, D'Errico A, Zironi G, Grigioni W, Bolondi L. What is the criterion for differentiating chronic hepatitis from compensated cirrhosis? A prospective study comparing ultrasonography and percutaneous liver biopsy. J Hepatol. 1997 Dec;27(6):979-85.</citation>
    <PMID>9453422</PMID>
  </reference>
  <reference>
    <citation>Koda M, Murawaki Y, Kawasaki H, Ikawa S. Portal blood velocity and portal blood flow in patients with chronic viral hepatitis: relation to histological liver fibrosis. Hepatogastroenterology. 1996 Jan-Feb;43(7):199-202.</citation>
    <PMID>8682462</PMID>
  </reference>
  <reference>
    <citation>Sacerdoti D, Merkel C, Bolognesi M, Amodio P, Angeli P, Gatta A. Hepatic arterial resistance in cirrhosis with and without portal vein thrombosis: relationships with portal hemodynamics. Gastroenterology. 1995 Apr;108(4):1152-8.</citation>
    <PMID>7698583</PMID>
  </reference>
  <reference>
    <citation>Schneider AW, Kalk JF, Klein CP. Hepatic arterial pulsatility index in cirrhosis: correlation with portal pressure. J Hepatol. 1999 May;30(5):876-81.</citation>
    <PMID>10365815</PMID>
  </reference>
  <reference>
    <citation>Bolognesi M, Sacerdoti D, Merkel C, Gerunda G, Maffei-Faccioli A, Angeli P, Jemmolo RM, Bombonato G, Gatta A. Splenic Doppler impedance indices: influence of different portal hemodynamic conditions. Hepatology. 1996 May;23(5):1035-40.</citation>
    <PMID>8621130</PMID>
  </reference>
  <reference>
    <citation>Bolognesi M, Sacerdoti D, Merkel C, Bombonato G, Gatta A. Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler. Ultrasound Med Biol. 2001 Jul;27(7):901-7.</citation>
    <PMID>11476922</PMID>
  </reference>
  <reference>
    <citation>Piscaglia F, Gaiani S, Calderoni D, Donati G, Celli N, Gramantieri L, Crespi C, Bolondi L. Influence of liver fibrosis on hepatic artery Doppler resistance index in chronic hepatitis of viral origin. Scand J Gastroenterol. 2001 Jun;36(6):647-52.</citation>
    <PMID>11424325</PMID>
  </reference>
  <reference>
    <citation>Lim AK, Patel N, Eckersley RJ, Kuo YT, Goldin RD, Thomas HC, Cosgrove DO, Taylor-Robinson SD, Blomley MJ. Can Doppler sonography grade the severity of hepatitis C-related liver disease? AJR Am J Roentgenol. 2005 Jun;184(6):1848-53.</citation>
    <PMID>15908541</PMID>
  </reference>
  <reference>
    <citation>Aubé C, Winkfield B, Oberti F, Vuillemin E, Rousselet MC, Caron C, Calès P. New Doppler ultrasound signs improve the non-invasive diagnosis of cirrhosis or severe liver fibrosis. Eur J Gastroenterol Hepatol. 2004 Aug;16(8):743-51.</citation>
    <PMID>15256975</PMID>
  </reference>
  <verification_date>March 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 25, 2007</study_first_submitted>
  <study_first_submitted_qc>April 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2007</study_first_posted>
  <last_update_submitted>March 5, 2008</last_update_submitted>
  <last_update_submitted_qc>March 5, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 6, 2008</last_update_posted>
  <responsible_party>
    <name_title>National Taiwan University Hospital</name_title>
    <organization>National Taiwan University Hospital</organization>
  </responsible_party>
  <keyword>Chronic hepatitis C</keyword>
  <keyword>Non-invasive diagnosis</keyword>
  <keyword>Duplex Doppler ultrasonography</keyword>
  <keyword>Biochemical indices</keyword>
  <keyword>Hepatic fibrosis</keyword>
  <keyword>Cirrhosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

